Therapeutics and COVID-19: living guideline - 16 September 2022
Geneve; WHO; Sept. 16, 2022. 141 p. ilus, tab, graf. (WHO/2019-nCoV/therapeutics/2022.5).
Non-conventional
em En
| BIGG, LILACS
| ID: biblio-1393164
Biblioteca responsável:
BR1.1
ABSTRACT
The WHO Therapeutics and COVID-19 living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges. This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
Assuntos
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
BIGG
/
LILACS
Assunto principal:
COVID-19
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Non-conventional
País de publicação:
Suíça